Petaluma, California (PRWEB) May 16, 2017
Hypochlorous acid was recently highlighted in an independent review published in the March 2017 issue of Journal of Drugs in Dermatology. Authored by Kristin Totoraitis BS, Joel L. Cohen, MD. and Adam Friedman, MD., the article assesses the impact of various agents encompassing topical antiseptics including chlorhexidine and povidone-iodine; topical antibiotics including neomycin and bacitracin; and hypochlorous acid (such as Sonoma’s patented Microcyn® Technology) on the optimization of post-surgical wound healing. Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA, warrants SNOAW), is a specialty pharmaceutical company that develops and markets unique and effective solutions for the treatment of dermatological conditions and advanced tissue care.
Although low risk, the report recognizes that one notable barrier to proper wound healing is surgical site infection. The use of various antibiotics and antiseptics attempt to address this issue, however these products are not without consequence. The overuse of topical antibiotics as a prophylaxis for infection has contributed to increased bacterial resistance, and in fact is no longer recommended by the American Academy of Dermatology in clean post-surgical wounds. Also noted in the report, topical antiseptics can have a cytotoxic effect on keratinocytes and may actually impede wound healing as a result. Some can actually produce both otologic and ocular toxic effects when used on the face, recently highlighted in the dermatologic literature
In summary, the report opines: “Emerging products, such as hypochlorous acid, may be a potential alternative to the more commonly used agents, as it has effective antimicrobial actions and minimal adverse effects.”
“Hypochlorous acid is a well-established broad-spectrum antimicrobial, anti-inflammatory and anti-itch agent that our own immune system produces for these important purposes,” said Adam Friedman, MD, and lead author of the report. “The overall issue with capitalizing clinically on these properties is both ease of application and product stability. A topical formulation that allows the patient to easily use hypochlorous acid with assured stability is highly advantageous.”
The abstract of the report can be found at: https://www.ncbi.nlm.nih.gov/pubmed/28301615
Sonoma Pharmaceuticals’ portfolio of hypochlorous acid-based dermatology products include Alevicyn™ Dermal Spray, Alevicyn™ Antipruritic Gel, Subuderm™ Topical Gel and Celacyn™ Scar Management Gel. More product information is available at http://www.intraderm.com, a fully owned subsidiary of Sonoma Pharmaceticals.
About Sonoma Pharmaceuticals, Inc.
Sonoma is a specialty pharmaceutical company that develops and markets unique and effective solutions for the treatment of dermatological conditions and advanced tissue care. The company’s products, which are sold throughout the United States and internationally, have improved outcomes for more than five million patients globally by reducing infections, itch, pain, scarring and harmful inflammatory responses. The company's headquarters are in Petaluma, California, with manufacturing operations in the United States and Latin America. European marketing and sales are headquartered in Roermond, Netherlands. More information can be found at http://www.sonomapharma.com.
Forward-Looking Statements
Except for historical information herein, matters set forth in this press release are forward-looking within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including statements about the commercial and technology progress and future financial performance of Sonoma Pharmaceuticals, Inc. and its subsidiaries (the “Company”). These forward-looking statements are identified by the use of words such as “believe,” “achieve,” and “strive,” among others. Forward-looking statements in this press release are subject to certain risks and uncertainties inherent in the Company’s business that could cause actual results to vary, including such risks that regulatory clinical and guideline developments may change, scientific data may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or approvals, clinical results may not be replicated in actual patient settings, protection offered by the Company’s patents and patent applications may be challenged, invalidated or circumvented by its competitors, the available market for the Company’s products will not be as large as expected, the Company’s products will not be able to penetrate one or more targeted markets, revenues will not be sufficient to fund further development and clinical studies, the Company may not meet its future capital needs, as well as uncertainties relative to varying product formulations and a multitude of diverse regulatory and marketing requirements in different countries and municipalities, and other risks detailed from time to time in the Company’s filings with the Securities and Exchange Commission including its annual report on Form 10-K for the fiscal year ended March 31, 2016. The Company disclaims any obligation to update these forward-looking statements, except as required by law.
Sonoma Pharmaceuticals®, IntraDerm Pharmaceutials®, Sebuderm™, Alevicyn™, Celacyn™ and Microcyn® Technology are trademarks or registered trademarks of Sonoma Pharmaceuticals, Inc. All other trademarks and service marks are the property of their respective owners.
Media and Investor Contact:
Sonoma Pharmaceuticals, Inc.
Dan McFadden
VP of Public and Investor Relations
(425) 753-2105
dmcfadden(at)Sonomais.com